| Literature DB >> 31636685 |
Chang Yu1, Ning Zhang1, Weikang Zhu2, Yueyue Zhang1, Jiao Yang1, Yong Wang2, Xiaoge Song3, Ling Hu3, Zijian Wu3, Qi Liu4, Yong Tang1, Qiaofeng Wu1, Shuguang Yu1.
Abstract
OBJECTIVES: To evaluate the safety of moxa smoke, especially to provide quantitative information and details for the occupational prevention of acupuncturists.Entities:
Year: 2019 PMID: 31636685 PMCID: PMC6766099 DOI: 10.1155/2019/4873235
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Demographic characteristics.
| Frequency ( | Constituent ratio (%) | |
|---|---|---|
| Gender | ||
| Male | 322 | 40.1 |
| Female | 481 | 59.9 |
| Age, mean | ||
| Male | 33.05 ± 0.443 | |
| Female | 30.74 ± 0.346 | |
| Age distribution | ||
| 20∼ | 393 | 49.1 |
| 30∼ | 273 | 34.0 |
| 40∼ | 101 | 12.6 |
| 50∼ | 33 | 4.1 |
| Average body mass index (BMI) | ||
| Underweight | 72 | 9.0 |
| Normal | 589 | 73.3 |
| Overweight | 119 | 14.8 |
| Obesity | 23 | 2.9 |
| Degree of education | ||
| Below undergraduate | 44 | 5.5 |
| Undergraduate and above | 759 | 94.5 |
| Ethnic | ||
| Han nationality | 782 | 97.5 |
| Others | 20 | 2.5 |
| Marital status | ||
| Unmarried | 289 | 36 |
| Married | 514 | 64 |
| Smoking status | ||
| Smoking | 92 | 11.5 |
| Used to smoke | 31 | 3.9 |
| Never smoke | 680 | 84.6 |
| Second-hand smoke exposure | ||
| No | 227 | 28.3 |
| Yes | 576 | 71.7 |
SD, standard deviation.
Figure 1Incidence of abnormal respiratory symptoms and respiratory diseases after MSE. (a) Incidence of abnormal respiratory symptoms after MSE. The highest was expectoration (18.7%), followed by shortness of breath (18.1%), wheezing (14.6%), chronic expectoration (14.4%), cough (12.6%), gasp for breath (5.7%), and chronic cough (4.9%). (b) Incidence of respiratory diseases after MSE. The highest was rhinitis (22.7%), followed by bronchitis (12.7%), pneumonia (8.3%), chronic bronchitis (2.6%), asthma (1.7%), and emphysema (0.1%).
Subgroup analysis: correlation between different MSE time of acupuncturists and abnormal respiratory symptoms and diseases prevalence.
| Cough (%) | Chronic cough (%) | Expectoration (%) | Chronic expectoration (%) | Wheezing (%) | Gasp for breath (%) | Shortness of breath (%) | Bronchitis (%) | Pneumonia (%) | Rhinitis (%) | Chronic bronchitis (%) | Emphysema (%) | Asthma (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Working years (years) | 1∼5 | 13.4 | 4.9 | 19.0 | 14.5 | 14.5 | 4.5 | 17.2 | 11.4 | 8.9 | 19.4 | 2.0 | NA | 1.3 |
| 6∼10 | 8.6 | 3.4 | 19.4 | 13.1 | 14.3 | 7.4 | 21.1 | 15.4 | 6.3 | 24.6 | 1.7 | NA | 1.1 | |
| 11∼20 | 11.1 | 4.4 | 18.9 | 16.7 | 14.4 | 8.9 | 12.2 | 15.6 | 7.8 | 26.7 | 5.6 | NA | 2.2 | |
| 21∼ | 20.7 | 8.6 | 22.4 | 19.0 | 13.8 | 8.6 | 24.1 | 12.1 | 5.3 | 39.7 | 3.4 | 1.7 | 3.9 | |
|
| 0.091 | 0.456 | 0.940 | 0.692 | 0.997 | 0.206 | 0.181 | 0.472 | 0.600 | 0.004 | 0.237 | 0.158 | 0.104 | |
|
| ||||||||||||||
| Average exposure each day (d·person·min) | 1∼30 | 11.3 | 3.9 | 17.8 | 11.7 | 14.8 | 3.9 | 15.7 | 10.0 | 7.0 | 22.2 | 1.3 | NA | 1.3 |
| 31∼120 | 15.6 | 5.0 | 19.4 | 17.5 | 13.1 | 7.5 | 8.1 | 10.0 | 6.3 | 21.9 | 3.1 | NA | 2.5 | |
| 121∼150 | 15.3 | 6.3 | 20.7 | 16.2 | 17.1 | 9.9 | 23.4 | 10.8 | 9.0 | 27.0 | 0.9 | NA | 2.7 | |
| 150∼ | 10.9 | 5.0 | 18.2 | 14.2 | 14.2 | 4.6 | 23.2 | 16.9 | 10.3 | 21.9 | 4.0 | 0.3 | 1.3 | |
|
| 0.363 | 0.810 | 0.917 | 0.413 | 0.830 | 0.086 | 0.001 | 0.053 | 0.389 | 0.704 | 0.159 | 0.646 | 0.637 | |
Notes. Average moxa smoke exposure each day = (average days of moxibustion activities per week (d) average number of patients per day (person) average duration of receiving moxibustion therapy per patient (min)) ÷ 7. P < 0.05 was recognized as significant difference between groups.
Demographic characteristics comparison between the moxa smoke-exposed and nonexposed group.
| Exposed group | Nonexposed group | |||
|---|---|---|---|---|
| Male ( | Female ( | Male ( | Female ( | |
| Gender | 73 (51.4) | 69 (48.6) | 73 (51.4) | 69 (48.6) |
| Age distribution | ||||
| 25–34 | 37 (26.1) | 36 (25.4) | 37 (26.1) | 36 (25.4) |
| 35–44 | 22 (15.5) | 20 (14.1) | 22 (15.5) | 20 (14.1) |
| 45–54 | 13 (9.2) | 11 (7.7) | 13 (9.2) | 11 (7.7) |
| ≥55 | 2 (1.4) | 1 (0.7) | 2 (1.4) | 1 (0.7) |
| Smoking status | ||||
| Smoking | 22 (15.5) | 0 | 22 (15.5) | 0 |
| Never smoke | 51 (35.9) | 69 (48.6) | 51 (35.9) | 69 (48.6) |
| BMI | ||||
| Underweight | 2 (1.4) | 8 (5.6) | 5 (3.5) | 14 (9.9) |
| Normal | 37 (26.1) | 53 (37.3) | 38 (26.8) | 43 (30.1) |
| Overweight | 26 (18.3) | 7 (4.9) | 25 (17.6) | 12 (8.5) |
| Obesity | 8 (5.6) | 1 (0.7) | 5 (3.5) | 0 |
Lung function comparison between the moxa smoke-exposed and nonexposed group.
| Variable | Exposed group (mean ± SD) | Nonexposed group (mean ± SD) |
|---|---|---|
|
| ||
|
| ||
| % predicted FEV1 | 103.98 ± 1.59 | 99.93 ± 1.67 |
| % predicted FEV1/FVC | 101.99 ± 0.94 | 100.92 ± 1.25 |
| % predicted VC | 106.64 ± 1.75 | 104.84 ± 1.35 |
| % predicted FVC | 102.39 ± 1.69 | 99.50 ± 1.59 |
| % predicted FEF25 | 87.11 ± 2.38 | 83.14 ± 3.03 |
| % predicted FEF50 | 93.37 ± 2.36 | 88.13 ± 2.54 |
| % predicted FEF75 | 97.78 ± 2.62 | 95.75 ± 2.99 |
| % predicted MVV | 106.23 ± 2.92 | 95.56 ± 1.92 |
| % predicted MMEF | 98.89 ± 2.37 | 98.43 ± 2.91 |
| % predicted PEF | 82.70 ± 2.34 | 79.80 ± 3.03 |
|
| ||
|
| ||
|
| ||
| % predicted FEV1 | 98.05 ± 1.51 | 94.57 ± 1.57 |
| % predicted FEV1/FVC | 101.25 ± 0.83 | 98.59 ± 1.16 |
| % predicted VC | 100.70 ± 1.59 | 95.91 ± 1.61 |
| % predicted FVC | 97.29 ± 1.69 | 96.43 ± 1.60 |
| % predicted FEF25 | 83.11 ± 2.18 | 79.64 ± 2.49 |
| % predicted FEF50 | 86.78 ± 1.98 | 82.15 ± 2.18 |
| % predicted FEF75 | 94.35 ± 2.70 | 90.69 ± 3.27 |
| % predicted MVV | 101.39 ± 2.46 | 98.39 ± 1.85 |
| % predicted MMEF | 100.61 ± 2.35 | 94.67 ± 2.84 |
| % predicted PEF | 81.48 ± 2.25 | 78.22 ± 2.73 |
P < 0.05 and P < 0.01 compared with the nonexposed group.
Figure 2Lung function comparison between the moxa smoke-exposed and nonexposed group. (a) Male lung function indexes comparison between the exposed and nonexposed group. Compared with the nonexposed group, the % predicted MVV index had statistical significance (106.23 ± 2.92 vs. 95.56 ± 1.92, P < 0.01). (b) Female lung function indexes comparison between the exposed and nonexposed group. Compared with the nonexposed group, the % predicted VC index had statistical significance (100.70 ± 1.59 vs. 95.91 ± 1.61, P < 0.05).